LANGHORNE, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter ended March 31, 2023, after the market closes on May 15, 2023.
Following the release of its financial and operating results, the Company will host a conference call at 4:30 P.M. ET on May 15, 2023. The conference call will be webcast live and can be accessed by registering on the Events and Presentations portion of NEXGEL’s Investor Relations website. The webcast will be archived for approximately 90 days.
NEXGEL First Quarter 2023 Financial Results Conference Call
Date: May 15, 2023
Time: 4:30 P.M. ET
Live Call: +1-888-886-7786 or +1-416-764-8658
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1609433&tp_key=21ca2e040e
For interested individuals unable to join the conference call, a replay will be available through May 22, 2023, at +1-844-512-2921 or +1-412-317-6671. Participants must use the following code to access the replay of the call: 37834998. An archived version of the webcast will also be available on NEXGEL’s Investor Relations site: https://ir.nexgel.com/.
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contacts:
Kelly Knobeck
Director of Consumer Products
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.31 |
| Daily Change: | -0.06 -1.78 |
| Daily Volume: | 500,080 |
| Market Cap: | US$22.470M |
November 13, 2024 November 11, 2024 October 10, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
